Biopharmaceutical company Oncothyreon Inc said a late-stage trial of its experimental lung cancer drug did not meet the main study goal of improving overall survival.
The drug, codenamed L-BLP25, is being tested in patients with unresectable, locally advanced stage IIIA or stage IIIB, non-small cell lung cancer (NSCLC).
The trial was conducted by Merck Serono, a division of Germany's Merck KGaA, under a license agreement with Oncothyreon.
Oncothyreon lung cancer drug fails in late-stage trial
This article
Oncothyreon lung cancer drug fails in late-stage trial
can be opened in url
http://newsopulence.blogspot.com/2012/12/oncothyreon-lung-cancer-drug-fails-in.html
Oncothyreon lung cancer drug fails in late-stage trial
